To start a compounded semaglutide telehealth business in 2026, sell access to a clinician-led program while licensed providers prescribe and a 503A pharmacy fills patient-specific orders. Budget for LegitScript, price against a $178 to $299 cash-pay market, and launch on a platform that tracks FDA changes for you.
Starting a compounded semaglutide telehealth business got a lot harder on February 21, 2025. That's the day the FDA declared the semaglutide shortage resolved, and it changed what pharmacies can make, how you can market a program and which business models still hold up in 2026.
If you're an operator, a med spa owner or a creator with an audience, you can still build this business. You just need to build it inside rules that are much tighter than they were in 2024. This guide walks you through those rules as they stand in November 2026, real launch costs with a Dallas example, the intake-to-refill workflow and the pharmacy questions to settle before your first patient signs up.
Executive Summary
Compounded semaglutide is still legal in 2026, but only in narrow cases. A 503A pharmacy can compound for an identified patient when the prescriber documents a significant clinical difference, and 503B outsourcing facilities have no current pathway. You don't need a medical license to own the business, because licensed clinicians make every prescribing decision. Your fixed launch costs are mainly LegitScript and your platform, and your profit depends on how many months each patient keeps refilling.
What Is a Compounded Semaglutide Telehealth Business?
It's a branded weight loss program you sell online, where the clinical and pharmacy work happens behind your storefront. Three questions come up first for most founders.
Is Compounded Semaglutide the Same as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved finished products. Compounded semaglutide is made by a state-licensed 503A pharmacy or a 503B outsourcing facility and doesn't go through FDA's premarket review, so the agency says it should only be used when an approved drug can't meet a patient's needs. That one rule shapes your pharmacy choice, your intake and every line of marketing copy you write.
Can Anyone Start a Telehealth Business?
Yes, you can own one without a medical license, as long as the clinical side stays with licensed providers. Many states follow a corporate practice of medicine rule that keeps medical decisions inside physician-owned practices, so founders who build from scratch usually set up a management company that runs marketing, billing and software while a physician-owned practice employs the clinicians. A white label platform gives you that structure already assembled, with providers licensed in each patient's state. Our broader guide covers the general setup for any specialty.
Can You Sell GLP-1 Online?
Yes, when what you're selling is access to a clinician-led program. A patient completes your intake, an independent clinician decides whether to prescribe, and a licensed pharmacy dispenses and ships. Your brand owns the price, the experience and the customer relationship, while prescribing and dispensing stay with licensed professionals.
Is Compounded Semaglutide Still Legal in 2026?
Yes, within limits that keep getting narrower. Here's the timeline that sets the rules for every semaglutide telehealth business today.
What Changed for Semaglutide Compounding Since 2025
| Date | What FDA did |
|---|---|
| Feb 21, 2025 | Declared the semaglutide injection shortage resolved |
| Apr 24, 2025 | Grace period for 503A pharmacies ended after a court denied an injunction |
| May 22, 2025 | Grace period for 503B outsourcing facilities ended |
| Mar 3, 2026 | Sent warning letters to 30 telehealth companies over compounded GLP-1 marketing |
| Apr 1, 2026 | Reminded compounders of the essentially-a-copy limits, including semaglutide and B12 blends |
| Apr 30, 2026 | Proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list |
| Jul 30, 2026 | Comment period on that proposal closed, with no final decision as of November 2026 |
What Is the Difference Between 503A and 503B Compounding Pharmacies?
A 503A pharmacy compounds for an identified patient against a prescription and answers mainly to its state board of pharmacy. A 503B outsourcing facility registers with FDA and makes larger batches, but it can only compound from bulk ingredients when the drug is on FDA's shortage list or the 503B bulks list. Semaglutide is on neither, and FDA's proposal would keep it off for good, so 503A is the route that matters this year.
Here's a detail most guides skip: FDA said it doesn't intend to act against a compounder that fills four or fewer prescriptions of an essentially copied product in a calendar month. That's a tiny ceiling, which is why serious programs build around documented, patient-specific need. Our 503A vs 503B breakdown goes deeper.
Why Semaglutide Salt Forms Are a Red Flag for Your Program
Some pharmacies turned to salt forms such as semaglutide sodium and semaglutide acetate as workarounds. FDA's position is direct: these are different active ingredients from the ones in approved drugs, and the agency says it isn't aware of any lawful basis for using them in compounding. If a pharmacy partner offers a salt form, treat that as your reason to walk away.
How Much Does It Cost to Start a Semaglutide Telehealth Business?
What Patients Pay for Compounded Semaglutide Online
Your price has to make sense next to what patients already see. Forbes Health's September 2026 review lists these monthly totals for compounded semaglutide, membership included:
| Platform | Monthly total |
|---|---|
| Mochi Health | From $178 |
| Henry Meds | From $297 |
| Remedy Meds | $299 ($179 first month) |
Brand-name pricing has moved closer, too. The same review lists Wegovy injections through NovoCare at $349 to $399 a month for cash-pay patients. So whether your patients live in Dallas, Chicago or Atlanta, a compounded program usually competes between $178 and $299, with brand-name Wegovy only $50 to $100 above the top of that range. Pricing far below the market can also look like the too-good-to-be-true discounts FDA lists as a telehealth red flag.
How Much Does It Cost to Start a Telehealth Business?
For a semaglutide program on a white label platform, these are the costs you can pin down before launch:
- LegitScript certification: $975 to apply, nonrefundable even if you're denied, plus $2,150 a year per website, according to LegitScript's fee sheet. One site costs $3,125 in year one, and our LegitScript guide covers the timeline.
- Platform: FUSE's free sandbox lets you build and test before you pay. Growth is $5,600 upfront, covering LegitScript coordination and your first month, then $699 a month. Partner is $30,000 with the first 12 months included, then $3,000 a month, per our pricing page.
- Payment processing: a 2% merchant service fee on Growth and Partner.
- Clinician, pharmacy and shipping costs: quoted per patient by your partners, so get them in writing before you set a price.
Our startup costs guide covers the rest, including legal review and marketing budgets.
Is a Semaglutide Telehealth Business Profitable?
It can be, as long as patients keep refilling. Picture a Dallas med spa that charges $249 a month and keeps 100 active patients on FUSE's Growth plan:
| Monthly line | Amount |
|---|---|
| Patient payments (100 x $249) | $24,900 |
| FUSE platform fee | $699 |
| Merchant fee at 2% | $498 |
| Clinician, pharmacy and shipping | Your partner quotes x 100 |
Year-one platform fees come to $13,289, including the $5,600 upfront payment. Model the per-patient clinical and pharmacy costs before you commit to a price.
Retention is where the profit sits. Prime Therapeutics found that 63% of commercially insured patients who started a GLP-1 for obesity in early 2024 were still on it a year later, up from 33% of 2021 starters. Its 2021 group shows how fast that fades, though: only 1 in 12 stayed on a GLP-1 for three years. Build your plan around realistic refill months, and use subscription refills and check-ins to keep patients engaged.
How a Compounded Semaglutide Telehealth Business Works From Intake to Refill
Can a Telehealth Doctor Prescribe Semaglutide?
Yes. GLP-1 medications aren't controlled substances, so the federal in-person rules for controlled drugs don't apply. Most semaglutide programs use asynchronous review, where a licensed provider works through a structured intake queue and decides without a scheduled video call. Some states expect a synchronous visit for certain prescriptions, so your platform should map modality rules by state before you open enrollment there.
The Five Workflow Stages Every Semaglutide Program Runs
- Structured intake: health history, current weight, prior treatment and consent, built short enough that people finish it and stored in HIPAA-ready systems covered by a business associate agreement.
- Asynchronous provider review: an independent licensed clinician reviews the submission and makes the prescribing decision, including any documented patient-specific need for a compounded preparation.
- Prescription and pharmacy routing: the approved prescription goes electronically to the configured pharmacy with no manual handoff.
- Fulfillment and updates: the pharmacy compounds the order, ships it in refrigerated packaging and triggers a notice at each milestone, from received to delivered.
- Refill cycle: check-ins, refill prescriptions and routing run on a schedule, which is where lifetime value is built.
How to Choose a Pharmacy and Platform for Your Semaglutide Telehealth Business
What to Ask a 503A Compounding Pharmacy for Semaglutide
Before you sign anything, get specific answers to these:
- Which pharmacies does the platform route semaglutide prescriptions to, by name?
- Is each one PCAB accredited, licensed in every state you serve and working to USP <797> sterile compounding standards?
- What are each pharmacy's current fulfillment times, measured in days?
- What happens to routing if a pharmacy's status changes mid-month?
- What's the documented basis for each compounded preparation, and is any salt form involved?
A platform that answers all of these with names and numbers is giving you real infrastructure. Vague reassurance is your cue to keep looking.
Which Telehealth Company Is Best for a GLP-1 Business?
The right partner depends on how much you want to own, but every shortlist should clear the same checks:
| What to check | Why it matters |
|---|---|
| 50-state licensed providers | You can sell wherever your audience lives |
| Qualified pharmacy network | Licensed in every state you serve, LegitScript certified and PCAB accredited |
| HIPAA infrastructure | Protects intake data and keeps an audit trail |
| LegitScript coordination | Unlocks ads and card payments sooner |
| Public pricing | No surprise per-visit or per-prescription fees |
FUSE Health is built for operators who want to own the brand while the clinical and pharmacy layers run behind the storefront. Every plan includes licensed providers in all 50 states, pharmacy fulfillment and HIPAA infrastructure, and fusehealth.com carries a LegitScript seal you can verify yourself. Partner pharmacies have to be licensed in every state served, LegitScript certified and PCAB accredited. You can see how an influencer brand launched its GLP-1 program, or how a med spa added telehealth revenue in 30 days.
How to Market a Semaglutide Telehealth Business Without FDA Warnings
What the FDA's 30 Warning Letters Flagged
On March 3, 2026, FDA warned 30 telehealth companies over compounded GLP-1 marketing, mainly for implying their products matched FDA-approved drugs and for selling compounded drugs under their own name without disclosing the real source. Keep your copy clear on three points: compounded means not FDA-approved, a licensed clinician decides eligibility, and the compounding pharmacy is named.
Ad Platform and Subscription Rules to Plan For
Google, Meta, Microsoft Bing and TikTok all recognize LegitScript certification, so plan on clearing it before you run a single prescription-related ad. Your checkout also needs clear recurring-billing terms and an easy way to cancel, which is what the federal Restore Online Shoppers' Confidence Act expects from subscription sellers and what the FTC has actively enforced. Our list of compliance tools covers what your platform should handle for you.
Building a Semaglutide Telehealth Business That Adapts as GLP-1 Rules Change
Why Your Workflow Should Outlast Any Single Compound
Switching to tirzepatide won't rescue a program that depends on volume compounding. Its shortage was resolved on December 19, 2024, and it sits in the same 503B proposal as semaglutide, so the safer play is a workflow that can carry brand-name GLP-1s, patient-specific compounded preparations and future approvals without a rebuild. Our compounded tirzepatide guide covers that choice.
Your Next Step With FUSE Health
Start with three lists: the states you want to serve, the GLP-1 options you plan to offer, and your answers to the pharmacy questions above. Bring them to a FUSE consultation and we'll map your provider coverage, pharmacy routing and LegitScript path, so you'll know exactly what launching a compounded semaglutide telehealth business will take.
This article is general information for business operators and isn't legal advice. Regulations and fees were current as of November 2026, so confirm them with qualified counsel before you launch.
References
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026)
- FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026)
- Forbes Health: 6 Cheapest Online Semaglutide Providers Without Insurance (published September 11, 2026)
- LegitScript: Healthcare Merchant Certification fact sheet (fees and recognizing platforms)
- Prime Therapeutics via BioSpace: Only 1 in 12 remain on a GLP-1 drug for obesity at three years (June 2025)
- Cooley: FTC Enhances Scrutiny of Subscriptions and Negative Option Features Under ROSCA (April 2024)
- FUSE Health pricing






